<DOC>
	<DOCNO>NCT02965053</DOCNO>
	<brief_summary>This study randomize study design 2x2 cross-over two period ( Period 1 Period 2 ) ass safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , efficacy EOS789 patient chronic kidney disease ( CKD ) hyperphosphatemia receive hemodialysis . Period 1 double-blind Period 2 open-label . Period 1 Period 2 identical regard design , inclusion/exclusion criterion , assessment . EOS789 combination sevelamer carbonate test Period 1 Period 2 respectively .</brief_summary>
	<brief_title>A Phase1 Study Explore Safety EOS789 Patients With Chronic Kidney Disease Hyperphosphatemia Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Patients CKD hyperphosphatemia must meet follow criterion study entry : Age ≥18 year On thriceweekly hemodialysis least 3 month prior screen Not change dialysis prescription within 4 week prior screen dialyzer , calcium concentration dialysate , dry weight 1 kg Receiving stable dos treatment affect serum phosphorus least 4 week prior screen willing discontinue treatment － Patients CKD hyperphosphatemia meet follow criterion exclude study entry : Uncontrolled diabetes and/or hypertension opinion investigator Uncontrolled chronic constipation and/or diarrhea opinion investigator Hospitalization cardiac disease previous 3 month Evidence acute chronic hepatitis know liver cirrhosis Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>